Trials / Completed
CompletedNCT00742469
Rifaximin for Prevention of Travellers' Diarrhea
A Randomized,Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Rifaximin for the Prevention of Travellers' Diarrhea
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
Detailed description
To determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin | |
| DRUG | Placebo |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2005-09-01
- Completion
- 2007-04-01
- First posted
- 2008-08-27
- Last updated
- 2019-12-18
- Results posted
- 2019-12-18
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT00742469. Inclusion in this directory is not an endorsement.